Cleerly has spent more than a decade performing some of the largest clinical trials to identify important findings beyond symptoms that increase a person’s risk of heart attacks. Cleerly goes beyond traditional measures of heart disease by enabling comprehensive quantification and characterization of plaque buildup in each of the heart arteries by using artificial intelligence-enabled analysis of a cardiac CT scan. This information supports physicians in the identification of plaques that may cause heart attacks which has been very difficult using traditional methods. Cleerly’s non-invasive, AI-driven approach supports the understanding of plaques using FDA-cleared technologies and enables patient-specific treatment based not solely on traditional risk factors, but on the patient’s own disease presence and extent.